Arkolith/Insider Trading/RXDX/Form 4

Marshall Keith W

Chief Financial OfficerPrometheus Biosciences, Inc. (RXDX) · full profile →Form 4 · filed Apr 7, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.1M
Net Open-Market Flow
-$1.1M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 5, 2023Sell(S)10K$108.42$1.1M10K
Apr 5, 2023Option exercise(M)10K$3.70$37K20K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 5, 2023Option exercise(M)10K—$093K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-023869) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML